Market Cap 90.43M
Revenue (ttm) 3.57M
Net Income (ttm) -7.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -218.49%
Debt to Equity Ratio 0.00
Volume 530,500
Avg Vol 187,894
Day's Range N/A - N/A
Shares Out 11.51M
Stochastic %K 65%
Beta 1.89
Analysts Strong Sell
Price Target $13.00

Company Profile

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 812 689 0791
Address:
11611 North Meridian St, Suite 330, Carmel, United States
crypto_biotech
crypto_biotech Apr. 26 at 10:30 PM
$NRXS Should hit $10 within 30 days.
0 · Reply
Finnish_boy
Finnish_boy Apr. 24 at 2:39 PM
$NRXS PUMP IT
0 · Reply
crypto_biotech
crypto_biotech Apr. 24 at 2:11 PM
$NRXS Bullish as hell.
0 · Reply
Finnish_boy
Finnish_boy Apr. 24 at 9:49 AM
$NRXS Looks like they chose pumping, maybe i have to buy more, risk is getting bigger for sooner take off when pumping happens in microcaps. https://mvcinvesting.substack.com/p/neuraxis-nrxs-the-pieces-are-lining
1 · Reply
crypto_biotech
crypto_biotech Apr. 24 at 1:00 AM
$NRXS Will be 100% YTD by June… probably before.
0 · Reply
Finnish_boy
Finnish_boy Apr. 23 at 11:35 AM
$NRXS Offering should be off the table when they announced new 10M ATM program. There will be more and more costs when they ramp up sales team. But revenue growth should be massive in H2 this year. I think SP stays around $7 for a while, in summer $10 and going to $15 this time next year.
2 · Reply
crypto_biotech
crypto_biotech Apr. 23 at 11:05 AM
$NRXS Pre-Market sign….
0 · Reply
Bobinato
Bobinato Apr. 22 at 3:48 PM
$NRXS wins a win but I thought carrico was done with small insurance press announcements
1 · Reply
stockinvestor102
stockinvestor102 Apr. 22 at 11:21 AM
$NRXS https://ir.neuraxis.com/neuraxis-expands-payer-coverage-with-four-new-medical-policies/
0 · Reply
Finnish_boy
Finnish_boy Apr. 22 at 8:43 AM
$NRXS Can be lame price action until major coverage news in June. Unless MVC group starts pumping (for a good reason, stock very undervalued). What do you think?
2 · Reply
Latest News on NRXS
NeurAxis, Inc. Announces Preferred Stock Dividend

Apr 10, 2026, 7:00 AM EDT - 16 days ago

NeurAxis, Inc. Announces Preferred Stock Dividend


NeurAxis Earnings Call Transcript: Q4 2025

Mar 19, 2026, 9:00 AM EDT - 5 weeks ago

NeurAxis Earnings Call Transcript: Q4 2025


NeurAxis Earnings Call Transcript: Q3 2025

Nov 11, 2025, 9:00 AM EST - 5 months ago

NeurAxis Earnings Call Transcript: Q3 2025


NeurAxis Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 11:00 AM EDT - 7 months ago

NeurAxis Transcript: Lytham Partners Fall 2025 Investor Conference


NeurAxis Earnings Call Transcript: Q2 2025

Aug 12, 2025, 9:00 AM EDT - 9 months ago

NeurAxis Earnings Call Transcript: Q2 2025


NeurAxis Announces $5.0 Million Registered Direct Offering

May 21, 2025, 7:00 AM EDT - 1 year ago

NeurAxis Announces $5.0 Million Registered Direct Offering


NeurAxis Earnings Call Transcript: Q1 2025

May 12, 2025, 9:00 AM EDT - 1 year ago

NeurAxis Earnings Call Transcript: Q1 2025


NeurAxis Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025, 5:00 PM EDT - 1 year ago

NeurAxis Transcript: Planet MicroCap Showcase: VEGAS 2025


NeurAxis Earnings Call Transcript: Q4 2024

Mar 20, 2025, 9:00 AM EDT - 1 year ago

NeurAxis Earnings Call Transcript: Q4 2024


NeurAxis Inc. Issues Letter to Shareholders

Jan 13, 2025, 9:00 AM EST - 1 year ago

NeurAxis Inc. Issues Letter to Shareholders


NeurAxis Earnings Call Transcript: Q3 2024

Nov 12, 2024, 9:00 AM EST - 1 year ago

NeurAxis Earnings Call Transcript: Q3 2024


NeurAxis Earnings Call Transcript: Q2 2024

Aug 9, 2024, 9:00 AM EDT - 1 year ago

NeurAxis Earnings Call Transcript: Q2 2024


NeurAxis Reports Second Quarter 2024 Financial Results

Aug 9, 2024, 8:00 AM EDT - 1 year ago

NeurAxis Reports Second Quarter 2024 Financial Results


NeurAxis Earnings Call Transcript: Q1 2024

May 22, 2024, 9:00 AM EDT - 2 years ago

NeurAxis Earnings Call Transcript: Q1 2024


NeurAxis Reports First Quarter 2024 Financial Results

May 22, 2024, 8:00 AM EDT - 2 years ago

NeurAxis Reports First Quarter 2024 Financial Results


NeurAxis Announces New Medical Policy Coverage in North Dakota

Apr 23, 2024, 9:00 AM EDT - 2 years ago

NeurAxis Announces New Medical Policy Coverage in North Dakota


NeurAxis Announces Highmark BCBS Policy Coverage

Mar 11, 2024, 9:00 AM EDT - 2 years ago

NeurAxis Announces Highmark BCBS Policy Coverage


NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

Jan 31, 2024, 9:00 AM EST - 2 years ago

NeurAxis Appoints Timothy Henrichs as Chief Financial Officer


NeurAxis Reports Third Quarter 2023 Financial Results

Nov 20, 2023, 5:30 PM EST - 2 years ago

NeurAxis Reports Third Quarter 2023 Financial Results


NeurAxis Announces CareFirst BCBS Policy Coverage

Nov 15, 2023, 9:00 AM EST - 2 years ago

NeurAxis Announces CareFirst BCBS Policy Coverage


NeurAxis Secures $3 Million Financing

Nov 14, 2023, 9:00 AM EST - 2 years ago

NeurAxis Secures $3 Million Financing


NeurAxis Reports Second Quarter 2023 Financial Results

Sep 21, 2023, 8:00 AM EDT - 2 years ago

NeurAxis Reports Second Quarter 2023 Financial Results


NeurAxis Highlights Pediatric Post-Concussion Clinical Study

Aug 29, 2023, 9:00 AM EDT - 2 years ago

NeurAxis Highlights Pediatric Post-Concussion Clinical Study


NeurAxis Highlights Strength of its Board of Directors

Aug 24, 2023, 9:00 AM EDT - 2 years ago

NeurAxis Highlights Strength of its Board of Directors


NeurAxis Announces Over $8 Million in IB-Stim™ Revenue

Aug 17, 2023, 9:02 AM EDT - 2 years ago

NeurAxis Announces Over $8 Million in IB-Stim™ Revenue


NeurAxis Announces Pricing of Initial Public Offering

Aug 9, 2023, 10:00 AM EDT - 2 years ago

NeurAxis Announces Pricing of Initial Public Offering


crypto_biotech
crypto_biotech Apr. 26 at 10:30 PM
$NRXS Should hit $10 within 30 days.
0 · Reply
Finnish_boy
Finnish_boy Apr. 24 at 2:39 PM
$NRXS PUMP IT
0 · Reply
crypto_biotech
crypto_biotech Apr. 24 at 2:11 PM
$NRXS Bullish as hell.
0 · Reply
Finnish_boy
Finnish_boy Apr. 24 at 9:49 AM
$NRXS Looks like they chose pumping, maybe i have to buy more, risk is getting bigger for sooner take off when pumping happens in microcaps. https://mvcinvesting.substack.com/p/neuraxis-nrxs-the-pieces-are-lining
1 · Reply
crypto_biotech
crypto_biotech Apr. 24 at 1:00 AM
$NRXS Will be 100% YTD by June… probably before.
0 · Reply
Finnish_boy
Finnish_boy Apr. 23 at 11:35 AM
$NRXS Offering should be off the table when they announced new 10M ATM program. There will be more and more costs when they ramp up sales team. But revenue growth should be massive in H2 this year. I think SP stays around $7 for a while, in summer $10 and going to $15 this time next year.
2 · Reply
crypto_biotech
crypto_biotech Apr. 23 at 11:05 AM
$NRXS Pre-Market sign….
0 · Reply
Bobinato
Bobinato Apr. 22 at 3:48 PM
$NRXS wins a win but I thought carrico was done with small insurance press announcements
1 · Reply
stockinvestor102
stockinvestor102 Apr. 22 at 11:21 AM
$NRXS https://ir.neuraxis.com/neuraxis-expands-payer-coverage-with-four-new-medical-policies/
0 · Reply
Finnish_boy
Finnish_boy Apr. 22 at 8:43 AM
$NRXS Can be lame price action until major coverage news in June. Unless MVC group starts pumping (for a good reason, stock very undervalued). What do you think?
2 · Reply
Finnish_boy
Finnish_boy Apr. 22 at 6:23 AM
$NRXS Q1 earnings still great catalyst when they will comment about outlook and give some sort of guidance + they will hint more about huge coverage wins ahead. 1 year PT $15.
1 · Reply
stockinvestor102
stockinvestor102 Apr. 22 at 2:07 AM
$NRXS “On a preliminary unaudited basis, we ex pect our cash and cash equivalents to be approx imately $7.1 million as of March 31, 2026. On a preliminary unaudited basis, we ex pect our net sales to be approx imately $1.6 million for the three months ended March 31, 2026, as compared to approx imately $0.9 million for the three months ended March 31, 2025. On a preliminary unaudited basis, we ex pect our gross profit to be approx imately $1.4 million, and our operating loss to be approx imately $1.7 million, for the three months ended March 31, 2026. As we complete our quarter-end financial statement close process and finalize our financial statements and accompanying notes for the three months ended March 31,2026, we will be required to make significant judgments in a number of areas that may result in the estimates provided herein being different than the final reported amounts.” https://s3.amazonaws.com/sec.irpass.cc/2940/0001493152-26-018361.pdf
0 · Reply
crypto_biotech
crypto_biotech Apr. 21 at 3:12 PM
$NRXS Undervalued. Re-rate coming. Bigger owns this Look at the one year or the YTD
0 · Reply
Doozio
Doozio Apr. 19 at 3:50 PM
$NRXS finishing up that first base and all da 🐑 been SPOT. Faatch 💣 or 🌙 ONTO 🐒🍌🧠⏰♾️
0 · Reply
TradeMachinist
TradeMachinist Apr. 17 at 1:42 PM
$NRXS is starting to get that early-stage attention profile — still under the radar, but the structure is interesting if you know what you’re looking at. TAM narrative is clearly way beyond current SP pricing Strong insider ownership = aligned incentives Notable larger capital positioning showing up Small float = moves can get nonlinear fast when liquidity shifts This is the type of setup where fundamentals + structure can disconnect from price until one catalyst forces repricing. Still early, still volatile — but the market tends to re-rate these names fast when participation steps in. Watching how volume behaves here more than anything.
0 · Reply
crypto_biotech
crypto_biotech Apr. 17 at 11:46 AM
$NRXS IBS symptom tracking IS messy with placebo, regression to the mean, and waxing/waning symptoms. That's exactly why the pivotal data for IB-Stim (PENFS) used a double-blind, randomized, sham-controlled RCT in 104 adolescents (Lancet 2017 + follow-on in CGH). Active arm hit 59% ≥30% worst-pain reduction vs 26% sham (p=0.0003). Not “some people think it works”—statistically superior to placebo device. And it’s not just one 9-week trial. NeurAxis now has 15+ peer-reviewed studies, including: • A 292-patient multicenter real-world registry (2024) showing sustained abdominal pain improvement at 6 and 12 months post 4-week treatment (p<0.001). • Comparative data vs standard meds (amitriptyline/cyproheptadine). • Microbiome and cost-effectiveness studies from independent centers. FDA-cleared for FAP associated with IBS (and later FD/nausea) in 8–21 y/o, now in major pediatric GI guidelines. Non-drug, low-risk option that’s helped a lot of kids who failed everything else.
0 · Reply
Finnish_boy
Finnish_boy Apr. 16 at 12:10 PM
$NRXS No-brainer for childrens/their families and doctors: no side effects and potentially great results that help to get back normal life. For shareholders, the invesment case is more no-brainer. Why? Bc nothing priced in. My 1 year PT $15
0 · Reply
alexpitti
alexpitti Apr. 15 at 5:39 AM
$NRXS the problem with measuring ibs is there is massive bias, mean regression, and naturally changing syptoms. making matters worse in kids/teens they can be misguided. placebo effect is huge. ib stim relies on only a 9 week rct trial. that's not enough to prove this works. put this device on your ear and your stomach pain will go away. some people think it works. but does it work? i have no idea
0 · Reply
crypto_biotech
crypto_biotech Apr. 14 at 3:29 PM
$NRXS Thanks to Biggee Capital for leading the way. Great DD!!
0 · Reply
focafoca99
focafoca99 Apr. 10 at 6:05 PM
$NRXS declared a dividend on its Series B preferred stock that will be paid in common shares based on accrued and unpaid dividends.
1 · Reply
Finnish_boy
Finnish_boy Apr. 9 at 7:36 PM
$NRXS I expect major coverage wins within 3 months. I have no idea when big insurances update their policies in case of PENFS but major news ahead.
1 · Reply
KyojuroRegn
KyojuroRegn Apr. 9 at 10:13 AM
$NRXS only 500 watchers need more people here
1 · Reply